Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...

Medical risk-based approaches outperformed age-based strategies, even when vaccine prices were low, the study authors said.

Covid-19 levels in the United States are high and rising, flu season is approaching quickly and RSV cases are already ...

Targeting vaccination programs for respiratory syncytial virus (RSV) to older adults with underlying health conditions is a ...

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The ...

Often dismissed as just another common cold, RSV can be deadly, especially for infants and older people. Hannah and her twin ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

(RSV) is a common cause of lower respiratory tract infection (LRTI) and is responsible for a high burden of hospital admission and mortality in children. RSV–LRTI is also associated with long-term ...

Older adults and newborn babies are among those ... option — is both safe and effective at preventing serious RSV infection in newborns, and protects babies even better than the vaccine given ...

Respiratory syncytial virus (RSV) is a common virus that usually causes mild, cold-like symptoms. You may have heard of ...

It’s that time of year again: the dreaded cold and flu season is on the horizon. But lurking in the shadows is a more sinister threat: RSV.